Premium
Allergic bronchopulmonary aspergillosis
Author(s) -
TillieLeblond I.,
Tonnel A.B.
Publication year - 2005
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.2005.00887.x
Subject(s) - allergic bronchopulmonary aspergillosis , medicine , bronchiectasis , itraconazole , exacerbation , immunology , cystic fibrosis , immunoglobulin e , asthma , allergy , aspergillosis , aspergillus fumigatus , antibody , lung , dermatology , antifungal
Allergic bronchopulmonary aspergillosis (ABPA) occurs in nonimmunocompromised patients and belongs to the hypersensitivity disorders induced by Aspergillus . Genetic factors and activation of bronchial epithelial cells in asthma or cystic fibrosis are responsible for the development of a CD 4 +Th2 lymphocyte activation and IgE, IgG and IgA‐AF antibodies production. The diagnosis of ABPA is based on the presence of a combination of clinical, biological and radiological criteria. The severity of the disease is related to corticosteroid‐dependant asthma or/and diffuse bronchiectasis with fibrosis. The treatment is based on oral corticosteroids for 6–8 weeks at acute phase or exacerbation and itraconazole is now recommended and validated at a dose of 200 mg/day for a duration of 16 weeks.